glp-1 molecular structure Crystal of the receptor bound to a peptide agonist PDB-101: Molecule of the Month:

Semaglutide, which acts on GLP-1 receptors in the gut, has the potential to modulate this microenvironment

Participants in semaglutide trials lost 1522% of body weight over 68 weeks while maintaining flexible eating patterns, suggesting the medication's appetite-suppressing power does substantial metabolic lifting

Clarification, April 1, 4:15 pm ET: A previous version of this post referred to the semaglutide revolution. The story has been updated to clarify that not all the medications for weight loss discussed are semaglutides.

Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues